This Microcap Just Locked In $20M, Setting the Stage for a Biotech Breakout

This glucose monitor maker just landed a $20 million deal to fuel its clinical pipeline, and Wall Street is piling in. With shares up over 100%, investors are betting the next chapter could be explosive.

The difference between “nice returns” and life-changing gains often comes down to timing—and information.

Our latest research has identified 5 stocks positioned for massive growth.

These companies combine strong fundamentals with technical setups that suggest the potential for explosive upside.

Past editions of this same report have included stocks that went on to gain +175%, +498%, even +673%.¹

While the past can’t predict the future, the track record speaks volumes.

For a limited time, you can download the full 5 Stocks Set to Double report—absolutely free.

[Get your free copy before midnight tonight]

Smart investors know: when the window is short, action beats hesitation.

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

U.S. stocks were mixed today as rising Treasury yields and weakening consumer sentiment pressured the Dow and S&P 500, while tech gains lifted the Nasdaq.

Eli Lilly (NYSE: LLY) is taking the fight with Novo Nordisk off the syringe and into the pill bottle. Its obesity pill, orforglipron, could launch next year in the U.S., putting it head-to-head with Novo’s oral semaglutide.

The stakes? A market projected to hit $80 billion by 2030, and whoever cracks oral delivery could control the biggest expansion phase of obesity drugs yet.

Convenience Could Be the Game-Changer

Lilly’s injectable Zepbound is still the heavyweight, with weight-loss results north of 20%. But injections come with limits; some patients hesitate, some drop out of treatment.

Oral options, even with slightly lower efficacy, could pull in millions more people. If pills become the go-to, Lilly’s scale gives it a chance to defend its turf.

Is that enough reason to get in now? That’s the question.

How Big Could This Get?

Wall Street already sees orforglipron pulling in over $14 billion a year by 2032. That’s not a side project, as it’s a whole new revenue engine.

The real stake isn’t about one study beating Novo. It’s about Lilly proving it can stay in the lead while the market itself explodes.

If the company holds its spot, this could still be one of the most compelling biopharma stories of the decade.

Boeing (NYSE: BA) is back in the hot seat.

The FAA is coming after it with a $3.1 million fine tied to safety violations on the 737 MAX, citing sloppy quality control and even pressure on an FAA rep to sign off on a plane that didn’t meet standards.

The number itself barely moves the needle — Boeing spends billions every quarter.

The problem is that every fresh fine adds to the story investors don’t want to hear: Boeing still hasn’t cleaned up its safety culture.

The Real Price Isn’t the Fine

The FAA still caps MAX output at 38 planes a month. If Boeing can’t convince regulators it has fixed its processes, that cap stays put.

More headlines, more inspections, and more scrutiny mean production delays, which directly hit deliveries and cash flow.

This isn’t about three million dollars. It’s about time, trust, and the company’s ability to prove it can finally run a clean shop.

Why It Keeps Hurting

Boeing keeps saying safety culture is improving. But every new violation gives airlines and regulators another reason to doubt the story.

That hands Airbus more credibility and pushes investors to keep pricing in risk.

The fine itself is chump change. The credibility gap is what keeps Boeing stuck, and until that changes, recovery stays on hold.

Geopolitical tensions and record highs in the Nasdaq are fueling a rush into U.S.-based AI leaders.

Smart money is targeting companies with real revenue, deep AI integration, and defense potential.

In my free report, “Top 9 AI Stocks for This Month,” you’ll discover:

With markets moving fast and defense budgets climbing, these stocks could break out any day.

[Get Your Free Copy Now] — before it’s behind a paywall.

Micron (NASDAQ: MU) has always been the chipmaker people mention after NVIDIA. But momentum is shifting, and more eyes are turning its way as AI demand fuels memory and storage chips.

Its last earnings came in stronger than expected, showing that the products it makes are in the right place at the right time.

That kind of demand isn’t a one-off.

Smaller Company, Bigger Upside

NVIDIA is a $4 trillion monster. Micron? About $150 billion. That size difference matters.

Adding $10 billion to Micron makes a dent, while NVIDIA has to move mountains to grow the same percentage.

That gap leaves Micron with more room to climb if demand keeps building. Sometimes it’s the smaller player in the right market that makes the faster move.

The Smart Money Is Already Moving

In September, traders piled into contracts tied to Micron’s future gains, showing conviction that the stock can push higher.

Big funds have been increasing their holdings too, signaling this isn’t just retail noise.

Here’s the simple way to think about it: getting into Micron now feels a lot like getting into NVIDIA before it became a household name.

If Micron keeps delivering like it has been, the payoff could look a lot like what early NVIDIA investors enjoyed.

👉 Click here to get our closing report to your cell for free!

GlucoTrack Inc [GCTK] $10.59 (+117.45%)

GlucoTrack climbed after securing a $20 million equity purchase agreement, giving it flexible funding to support operations and clinical goals.

HCW Biologics Inc [HCWB] $5.59 (+68.37%)

HCW Biologics gained after unveiling promising preclinical data on its second-generation T-cell engagers, positioning the company for high-value partnership opportunities.

IBEX Ltd [IBEX] $41.58 (+36.51%)

IBEX soared after delivering record Q4 and FY25 earnings, with AI deployments entering full-scale rollout and driving future growth optimism.

Rent The Runway Inc [RENT] $5.02 (-36.38%)

Rent the Runway crashed as widening losses and falling gross margins overshadowed upbeat subscriber growth and a major recapitalization plan.

Frequency Electronics Inc [FEIM] $27.13 (-21.02%)

Frequency Electronics sank after reporting a 45% drop in operating income and weaker Q1 revenue, despite management blaming timing delays and reaffirming a strong outlook.

Moderna Inc [MRNA] $23.51 (-7.40%)

Moderna fell after reports claimed Trump health officials may tie COVID vaccines to child deaths, sparking a broad selloff across vaccine makers.

The market’s wild swings—like a 427‑point drop one day and a 619‑point rally the next—are enough to make anyone’s head spin.

With Washington trade talks and Fed policy chatter fueling volatility, you need a proven playbook.

Grab our FREE e‑book, Mastering Options Trading: A Beginner’s Guide, and discover:

Don’t let this chaos pass you by.

Download your guide now and trade uncertainty like a pro!

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.